

In the Specification

Please amend paragraph [0005], page 2 as follows:

[0005] U.S. Patent Nos. 4,532,215 and 4,636,469 described, respectively, a strain of wild-type HAV, designated HM-175, initially isolated from the feces of a patient, and adapted to passage *in vitro* in African green monkey kidney culture cell and methods for obtaining a vaccine by serial passaging. Also, CN Patent Nos. 85107525-89106580.6 and 92114998 disclose the preparation of attenuated HAV designated H₂-and L-A-1, respectively.

Please amend paragraph [0006], page 2 as follows:

[0006] With regard to live attenuated hepatitis A vaccine, it is worth mentioning the live HAV vaccine based on strain CR*326F (Merek & Co. Inc.), which is under preclinical trials, and the vaccines based on strain H₂ and L-A-1, respectively, have been licensed for practical use and industrial-scale production in China. Clinical serological studies demonstrated that these live attenuated hepatitis A vaccines, especially the vaccine prepared from L-A-1 strain of HAV (produced by Changchun Institute of Biological Products Ministry of Public Health, Changchun, China) evoked high titers of antibody response, in most volunteers receiving the vaccine, after only one dose and no systemic complains were present immediately after vaccination or during long-term follow-up (see CN Patent No. 92114988 92114998)